RTI Surgical (RTIX) Reports In-Line Q3 EPS; Trims FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Canaccord Genuity Downgrades RTI Biologics (RTIX) to Hold
October 30, 2015 8:07 AM EDTCanaccord Genuity downgraded RTI Biologics (NASDAQ: RTIX) from Buy to Hold with a price target of $4.00.
For an analyst ratings summary and ratings history on RTI Biologics click here. For more ratings news on RTI Biologics click here.
Shares of RTI Biologics closed at $4.40 yesterday.
... More